Atley Solutions and Perceptive Discovery today announced the sale of two Atley C100 modules to Perceptive Discovery, marking the first step in a strategic collaboration aimed at establishing robust ...
Hosted on MSN
Targeted alpha therapy using astatine shows promise in thyroid cancer resistant to conventional treatment
A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, ...
Hosted on MSN
Curadh MTR and Alpha Fusion to Spotlight Breakthrough Cancer Therapy at Radiopharmaceutical Summit
CHESTER SPRINGS, PA — Curadh MTR Inc. and Alpha Fusion, Inc. are set to showcase advances in cancer treatment using Astatine-211 (At-211) radiopharmaceuticals at the upcoming 4th Targeted ...
Naya Therapeutics Inc. is expanding its hepatocellular carcinoma pipeline with the addition of NY-700, a first-in-class GPC3-targeted Astatine-211 (211At) α radioimmunotherapy aiming to address ...
A team at Texas A&M University has developed an automated system for separating and shipping At-211. This patent-pending device enables the radioisotope to be purified and loaded as part of the ...
Reston, VA (December 4, 2025)--A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results